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Background: Allergen-specific immunotherapy (SIT) is a treatment capable of modifying the 
natural course of allergy, so ensuring good adherence to SIT is fundamental. Up until now there 
has not existed an instrument specifically developed to measure patient satisfaction with SIT, 
although its assessment could help us to comprehend better and improve treatment adherence 
and effectiveness. The aim of this study was to develop an instrument to measure adult patient 
satisfaction with SIT.
Methods: Items were generated from a literature review, focus groups with allergic adult 
patients undergoing SIT, and a meeting with experts. Potential items were administered to 
allergic patients undergoing SIT in an observational, cross-sectional, multicenter study. Item 
reduction was based on quantitative and qualitative criteria. A preliminary assessment of 
  feasibility,   reliability, and validity of the retained items was performed.
Results: An initial pool of 70 items was administered to 257 patients undergoing SIT. 
  Fifty-four items were eliminated resulting in a provisional instrument with 16 items. Factor 
analysis yielded four factors that were identified as perceived efficacy, activities and environ-
ment, cost-benefit balance, and overall satisfaction, explaining 74.8% of variance. Ceiling and 
floor effects were negligible for overall score. Overall score was associated with the type and 
intensity of symptoms.
Conclusion: This is the first attempt to develop a satisfaction with SIT measure from the 
perspective of the allergic patient, and evidence has been found in favor of its reliability and 
validity.
Keywords: allergy, allergen-specific immunotherapy, questionnaire, scale, assessment, 
satisfaction
Introduction
Treatment satisfaction is defined as the individual’s rating of important attributes of 
the process and outcomes of his/her treatment experience.1 While health status instru-
ments measure the results of treatment, eg, in perceived biological, symptomatic or 
welfare (quality of life) terms, treatment satisfaction scales assess the level of satis-
faction with the said results,2 so that presumably, assessment of patient satisfaction 
with treatment could contribute to understanding and improving treatment adherence 
and thereby improve results with regard to health. Some years have passed since the 
first conceptual approaches,1 up to subsequent revisions,2,3 and there seems to be a 
certain consensus, in that patient satisfaction with treatment is influenced by patient Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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  characteristics (eg, their preferences and expectations), 
the characteristics of the health problem being treated 
(eg, symptom severity), the characteristics of pertinent health 
care system and, obviously, the characteristics of the treat-
ment in question (ie, effectiveness, discomfort, cost, adverse 
effects, and associated limitations of the medication). The 
assessment of patient satisfaction with treatment should con-
template these aspects, and should be carried out with duly 
developed instruments that take into account the patient’s 
perspective during its development.1–3 Currently, there 
already exist multidimensional scales that assess treatment 
satisfaction (referring solely to the medication employed or 
including other aspects relative to the treatment) regarding 
different illnesses4–8 or symptoms.9–12 There are also more 
generic instruments, eg, that assess the chronic patient’s 
treatment satisfaction in general, as is shown in the case of 
the Treatment Satisfaction Questionnaire for Medication that 
includes dimensions common to chronic treatments13,14 or 
other scales.15 In this way, the same thing probably happens 
with regard to patient satisfaction as it does in health-related 
quality of life assessment, where specific and generic instru-
ments are complementary because they contribute different 
kinds of information and achieve different objectives.
Allergy prevalence is growing worldwide,16 and its 
therapeutic management often employs on-demand symp-
tomatic treatment to minimize the symptoms as a comple-
ment to allergen-specific immunotherapy, a treatment that 
is capable of modifying the natural course of the illness,17,18 
so ensuring good adherence to this treatment is fundamental. 
However, as happens with chronic treatment, patients receiv-
ing allergen-specific immunotherapy can be noncompliant, 
mainly due to inconvenience, a feeling of inefficacy, cost, 
and side effects.19,20 Theoretically, this lack of adherence 
minimizes the effectiveness of the treatment, has repercus-
sions on patient satisfaction, and reinforces noncompliance, 
as was found with other chronic illnesses, such as diabetes21 
and human immunodeficiency virus infection.22 Given that 
treatment satisfaction has been associated with the willing-
ness to continue the said treatment,23 one could hypothesize 
that the more the patient is satisfied with his/her specific 
immunotherapy, the more likely he/she will be to adhere to 
and comply with the treatment over the treatment period.
Materials and methods
The three main phases of the project consisted of item genera-
tion, item reduction with data collected in a first field-work 
study, and an exhaustive assessment of the psychometric 
properties of the questionnaire’s final version, with data 
collected in subsequent field work. This paper reports the 
main results of the first two steps of the overall project 
(Figure 1).
item generation
The content of the questionnaire was developed from 
  November 2008 to March 2009 from a literature review, 
focus groups and expert opinions from allergologists and 
experts in the development of patient-reported outcomes 
(PRO) measures. The literature review included a search 
of the Medline database (1966–2008) using search terms, 
including “patient satisfaction”, “treatment satisfaction”, 
“questionnaire”, “scale preferences”, “respiratory”, and 
“allergy”. The articles located were searched manually for 
further relevant articles. The review of instruments was 
mainly intended to identify the usual questionnaire content 
at domain level.
The initial consultation with experts (allergologists and 
experts in the development of PRO measures) took place at 
a meeting in Madrid. We used a structured brainstorming 
technique to establish the experts’ views on the potential 
content, usefulness, and formal characteristics of the new 
questionnaire that would make it practical for use in standard 
clinical practice.
Three focus groups were formed24 in the allergy depart-
ments at three different health centers in Madrid, Pamplona, 
and Seville where three of the study investigators are located 
(PO, JMO, and PG, respectively). Each center selected 7–9 
candidate patients to participate in the sessions on the basis 
of the following requirements: they had to be patients with 
allergy over 18 years of age and been undergoing specific 
immunotherapy treatment for at least four months. Each 
group was to be well balanced as to gender, sociocultural 
status, (high, middle, or low), the allergen to which they 
were allergic (pollens and/or dust mites), the kind of set pat-
tern (preseasonal or perennial), and the method of specific 
  immunotherapy administration (subcutaneous or sublingual). 
All participants gave their formal consent to participate.
The meetings were led by a moderator assisted by a script 
specifically developed for this purpose. The script included 
questions about aspects that the experts had considered as 
potentially relevant in the initial consultation, as well as ques-
tions to identify other aspects not identified by the experts 
but which were considered relevant by the participating 
patients (ie, Which aspects do you feel are important for 
you to be satisfied with an allergy vaccine? What aspect do 
you consider to be most important regarding your allergy 
vaccine? What don’t you like about your allergy vaccine?). Patient Preference and Adherence 2011:5
Literature review
3 focus groups
Initial list of 179 statements
Pool of 70 candidate items
Definitive 16-item version obtained
Validation measure field work
(currently in progress)
Item reduction fieldwork
(N = 257 patients)
Expert metaplans
Definition of the requirements that the new 
measure should comply with.
Guideline to moderate focus groups with patients
Session transcription. Content analysis
Statistical analysis and expert opinion for item reduction. Preliminary
psychometric properties tested.
Linguistic revision: initial shortlisting  based on criteria of
understandability, redundancy, irrelevance, and adjustment to
goal measure’s. Administered to 6 allergic patients. Design of  
response option and timeframe.
Figure 1 Overview of study procedures.
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A content analysis of transcripts from the focus groups was 
performed by two of the study team members, and the results 
were used to develop an initial pool of items for inclusion in 
the questionnaire. This pool was administered to six allergic 
patients other than those who participated in the focus groups, 
so that redundant items as well as those ambiguous or lacking 
in face validity were omitted. The wording and phrasing used 
by focus group members was retained wherever possible. An 
agreement was reached with clinical experts on using “two 
months” as a suitable time frame for items in the pool. All the 
aforementioned procedures were carried out in Spanish.
item reduction
study design and participants
The pool of items considered for inclusion in the final 
version of the questionnaire was administered to allergic 
patients undergoing allergen-specific immunotherapy in an 
observational, cross-sectional, multicenter study performed 
between June 2009 and September 2009 in the allergy units 
of 20 Spanish hospitals or health care centers. Each centre 
consecutively included patients 18 years old or over, with a 
diagnosis of respiratory allergy, who had received or were 
receiving immunotherapy with aeroallergens (pollens or 
mites) by the subcutaneous or sublingual route, for at least 
six months constantly and/or for a minimum of two specific 
immunotherapy preseasonal cycles. All patients provided 
their informed consent to participate in the study. The study 
was conducted according to the Declaration of Helsinki 
and was approved by the Ethics Committee of the Hospital 
Universitari Vall d’Hebron in Barcelona.
Data were collected about the patient’s gender, age, and 
level of education. The clinical characteristics recorded 
included time since diagnosis, allergen sensitization, comor-
bidities, type and intensity of main symptoms, type and regi-
men of allergen-specific immunotherapy, and symptomatic 
treatment. All patients included in this phase of the study 
were asked how frequently they experienced the situation 
presented in each of the items and whether the item was 
important to them, each on five-point scales.
statistical analysis
Item reduction involved a series of steps: missing responses 
were analyzed to exclude those items with a relevant per-
centage of responses missing; the response distribution was 
analyzed and items with endorsement rates (percentage of 
respondents that checked the same response category) of Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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over 70% were excluded;25 and the frequency and impor-
tance scores were analyzed for each item. In this part of the 
item reduction process, the product of the frequency and 
importance scores (the “impact” score) was obtained for each 
item and then ranked and selected according to this prod-
uct; redundancy of items was also taken into consideration 
throughout the item reduction process; the decision about 
which items to retain when redundancy or high correlations 
occurred (Pearson .0.85) was based on the relative clinical 
relevance of the items; and the relationships between all items 
and their posited scales were analyzed by the calculation of 
corrected item-scale correlations and analysis of the impact 
on Cronbach’s alpha values.
Using the data collected in the item reduction study, 
and with the aim of initially exploring the questionnaire 
performance, the internal consistency, construct validity 
(known-groups), and content validity26 (factor analysis by 
means of principal component analysis, Varimax rotation) 
were assessed for the retained items. Following the recom-
mendations set out in the literature,25,27 the overall score for 
the final version of the questionnaire was obtained by adding 
the scores from all the items, and the score for each dimen-
sion was obtained by adding the scores for the items in that 
dimension. For individual patients included in the study, 
overall scores were not calculated when the questionnaire 
had any item missing. The distribution of the overall and 
dimension scores was described by calculating score range 
and floor/ceiling effects (the proportion of patients with the 
worst and the best possible scores, respectively). Reliability 
for the overall score and dimension score was assessed in 
terms of internal consistency using Cronbach´s alpha (values 
of 0.70 or over are considered adequate).25 A preliminary 
assessment of the prevalidated questionnaire was tested by 
determining whether the instrument was able to discriminate 
between patient groups likely to differ in patient-satisfaction 
with specific immunotherapy. It includes type and intensity 
of allergic rhinitis according to the Allergic Rhinitis and its 
Impact on Asthma guidelines,16 and symptomatology (pres-
ence and intensity of rhinorrhea and sneezing) as the tested 
independent variables.
Results
item generation
The literature review identified 17 citations that were con-
sidered potentially relevant to the study, which identified 
several instruments or surveys of interest, mainly focused 
on preferences and satisfaction with inhalation devices in 
asthma,28,29 satisfaction with asthma health care services,30,31 
satisfaction with corticosteroid treatment for asthma,32 and 
allergies treated with sublingual allergen-specific immu-
notherapy that included some questions about satisfaction 
with treatment.33
Asked to consider the three main issues addressed in the 
brainstorming session, the experts mentioned the following 
as the most relevant questions to be attended to for the devel-
opment of the questionnaire: treatment efficacy, cost, daily 
inconveniences derived from the logistics of administering 
the treatment, adverse reactions, and the way of administer-
ing the treatment. They also thought that the questionnaire 
should be useful in clinical practice, especially to improve 
treatment compliance (eg, helping to identify patients who 
risk abandoning the treatment), to provide relevant informa-
tion on decisions to be taken after beginning allergen-specific 
immunotherapy, as well as to be brief, easy to score and use, 
and preferably self-administered.
A pool of 70 items was generated with the information 
obtained from the 24 participants in the focus group, together 
with input from the literature review and the brainstorming 
with experts.
item reduction and preliminary validation
The pool of items was administered to 257 allergic patients, 
mostly young adults, well balanced in gender and with high 
educational levels. The study sample had been diagnosed as 
having had a respiratory allergy for more than seven years, 
mainly due to pollen. At the time of inclusion, the study sample 
showed a considerable level of symptoms. All the patients 
were undergoing allergen-specific immunotherapy treatment, 
mainly by the subcutaneous route (63.4%, see Table 1).
Fifty-four of the initial 70 items included in the item 
reduction phase were eliminated. The reasons for their elimi-
nation and the number of items eliminated for each reason are 
shown in Figure 2. With respect to the quantitative criteria 
applied for the process of item reduction, three of them, ie, 
poor response distribution, impact score and ranking (see 
summary in Table 2), and internal consistency parameters 
(item-total correlation and contribution to Cronbach’s alpha) 
were found to be the most efficient, and responsible for elimi-
nating 47 of the initial items. Six items were eliminated due to 
qualitative criteria, leaving a prevalidated version containing 
16 items, the length of which would presumably be more 
apt for use in clinical practice. The decision regarding the 
elimination of each of the six items was widely discussed 
and taken by general consent by the group of investigators 
based on the face validity of the item, its redundancy, and 
the length or complexity of wording.Patient Preference and Adherence 2011:5
Table 1   Demographic  and  disease  characteristics  of  patients 
involved in quantitative item reduction (n = 257)
Gender, women, n (%) 133 (51.8)
Age, years, mean (sD) [min, max]  33.2 (10.7)   
[18, 7]
Educational level, n (%)
no formal education 9 (3.5)
Primary education 48 (18.7)
secondary education 103 (40.1)
University or similar 94 (36.6)
Missing data 3 (1.1)
Time since diagnosis, years, mean (sD) 7.7 (7.4)
Allergen, n (%)
Mite 72 (28.0)
Pollen 162 (63.0)
Both 20 (7.9)
Missing data 3 (1.1)
Comorbidities, n (%)a
Asthma 138 (53.7)
conjunctivitis 190 (73.9)
Other comorbidities 11 (4.3)
Type of asthma, n (%)b
Mild intermittent 82 (59.4)
Mild persistent 26 (18.8)
Moderate persistent 24 (17.5)
severe persistent 2 (1.4)
Missing data 4 (2.9)
Type of allergic rhinitis, n (%)
Persistent 99 (38.5)
intermittent 140 (54.5)
Missing data 18 (7.0)
Severity of allergic rhinitis, n (%)c
Mild 83 (32.3)
Moderate 122 (47.5)
severe 49 (19.1)
Missing data 3 (1.1)
Type of allergen-specific immunotherapy, n (%)d
sublingual 93 (36.2)
subcutaneous 163 (63.4)
Both 1 (0.4)
Allergen-specific immunotherapy regimen, n (%)d
Perennial 202 (78.6)
Preseasonal 44 (17.1)
Missing data 11 (4.3)
Symptomatic treatment, n (%)d
corticosteroids 26 (10,1)
Antihistamines 61 (23.7)
Both 128 (49.8)
Others 53 (20.6)
Notes: aPatient could respond to more than one option; bAccording to the global 
Initiative for Asthma classification;17 cAccording to Valero et al;42 dAt inclusion.
Abbreviations: sD, standard deviation; min, minimum; max, maximum.
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In the factorial analysis done on the 16 retained items 
(Table 3), a four-factor solution was found that explained 
74.8% of variance, with item-loading values ranging from 
0.441 to 0.858. The assignment to the final dimensions of 
those items that contributed to two different factors was 
  performed by clinical criteria, so that the prevalidated ques-
tionnaire consisted of 16 items distributed in four dimensions, 
ie, perceived efficacy (four items), activities and environment 
(six items), cost-benefit balance (three items), and overall 
satisfaction (three items).
Table 4 shows the score distributions, floor/ceiling effects, 
and internal consistency for the prevalidated questionnaire. 
In total, 33.5% of the sample had at least one item missing 
of the 16 retained. Ceiling and floor effects were negligible 
(,5%) in all dimensions and for the overall score, except for 
the ceiling effect of cost-benefit balance and overall satisfac-
tion dimensions, for which almost 23% and 16% of patients 
obtained the best possible scores. Cronbach´s alpha values 
were more than 0.70 for the overall score (0.94) and for all 
dimensions (0.79–0.89).
Table 5 shows the results of testing the validity of the 
prevalidated questionnaire in the known groups. Patients 
with intermittent allergic rhinitis, mild allergic rhinitis (and 
specifically those with no troublesome symptoms according to 
Allergic Rhinitis and its Impact on Asthma classification) and 
those without sneezing symptoms, reported statistically signifi-
cant (P = 0.051–0.039) better (higher) global scores than did 
patients with persistent allergic rhinitis, those with moderate/
severe intensity of allergic rhinitis, those reporting troublesome 
symptoms of allergic rhinitis and asthma, and those report-
ing sneezing symptoms. Statistically significant associations 
were not found between the questionnaire scores with regard 
to age, gender and type of allergen-specific immunotherapy 
(sublingual versus subcutaneous, data not shown).
Discussion
According to some authors, working within the patient 
satisfaction environment, there are several reasons why we 
should assess satisfaction with medication. On the one hand, 
although there are few existing developed studies, the relation 
between satisfaction with medication and medication com-
pliance should be considered. On the other hand, knowing 
the patient’s satisfaction with respect to a certain medication 
could lead to the improvement of products,3 that is to say, in 
the adaptation of the same to the requirements and expecta-
tions of the patient in question. Furthermore, assessment of 
satisfaction with medication would be particularly recom-
mendable, for instance, in comparing similarly effective 
kinds of medications with different routes of administration, 
different profiles regarding side effects, or when the treatment 
plays a principal role in a certain therapeutic approach.3 All 
this reasoning fits in perfectly with the case of the allergic 
patient undergoing specific immunotherapy, where the Patient Preference and Adherence 2011:5
Initial pool of 70 items
No item removed because of missing reponses
11 items removed because of response distribution
(>60% of the sample in one only answer option)
20 items removed because of low ranking
7 items removed because of low item–total correlation
1 item removed because of redundancy
(Pearson correlation >0.85)
Version 1.0 of the new questionnaire (22 items)
6 items removed on the basis of clinical opinion
Final 16-item prevalidated version of 
the new questionnaire
9 items removed for decreasing Cronbach’s alpha
70 items
59 items
39 items
32 items
23 items
22 items
Figure 2 items eliminated at different stages of the item reduction process.
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Table 2 highest scoring items of the original 70 items (n = 254)
Mean (SD)  
frequency
Mean (SD)  
importance
Mean (SD)  
impact scorea
The vaccine is compatible with my life style 1.6 (0.9) 1.7 (0.9) 2.9 (2.3)
My vaccine is easy to administer 1.7 (1) 1.6 (0.8) 3 (2.7)
Generally speaking, I am satisfied with my allergy vaccineb 1.8 (1.1) 1.5 (0.7) 3 (2.8)
My vaccine worksb 2.1 (1) 1.5 (0.7) 3.2 (2.5)
since being vaccinated i have felt much better 2 (1) 1.5 (0.7) 3.3 (2.7)
since being vaccinated for the allergy i present fewer symptomsb 2.1 (1) 1.5 (0.7) 3.5 (2.4)
i have fewer allergy crises, thanks to the vaccine 2.1 (1.1) 1.5 (0.7) 3.5 (3.1)
in general, i would recommend the vaccine treatmentb 1.7 (1) 1.9 (0.9) 3.6 (3.4)
The medical treatment i receive helps me with the vaccine treatment 1.8 (0.9) 1.8 (0.9) 3.8 (4)
i have felt better since receiving the vaccine 2.1 (1) 1.7 (0.8) 3.8 (3.1)
My quality of life has improved since receiving the vaccineb 2.2 (1.1) 1.6 (0.7) 4 (3.6)
My vaccine gives me independence 2 (1.2) 1.8 (0.9) 4.1 (4.2)
The information i received at the start of the vaccine treatment has 
helped me to understand how it works
1.9 (1.1) 19 (0.9) 4.2 (3.9)
The good performance of the vaccine compensates for having  
to take it daily
2.1 (1.2) 1.8 (1) 4.3 (4.1)
The good performance of the vaccine compensates for any  
inconveniences it could cause meb
2.1 (1.1) 1.9 (0.9) 4.3 (3.7)
The good performance of the vaccine compensates for the  
financial challenge it causes meb
2.2 (1.2) 1.8 (0.9) 4.4 (3.7)
The good performance of the vaccine compensates for all the  
things i have to do to obtain it (appointments, prescriptions, leave)b
2.2 (1.2) 1.9 (1.5) 4.6 (3.9)
My vaccine doesn’t produce side effects 2.4 (1.6) 1.7 (1) 4.7 (5.6)
Thanks to the vaccine i can work or study betterb 2.5 (1.2) 1.9 (1) 5.4 (5.1)
Thanks to the vaccine i only need an inhaler or take pills at certain  
or isolated times
2.5 (1.4) 1.9 (1) 5.4 (5.3)
if i had known about the vaccine before i would have started  
with it earlier
2.3 (1–3) 1.9 (1) 5.4 (5.5)
since receiving the vaccine i enjoy outdoor activities moreb 2.5 (1.2) 2 (1) 5.5 (4.9)
My vaccine helps me feel better physically 2.5 (1.1) 1.9 (0.9) 5.6 (4.8)
getting vaccinated is easy and quite quick 2.5 (1.3) 2.1 (1) 5.7 (4.3)
My vaccine works faster than i had expectedb 2.8 (1.2) 1.9 (0.9) 5.8 (4.4)
since being vaccinated i don’t continually interrupt my activities  
due to allergy symptoms
2.6 (1.2) 2 (0.9) 5.8 (4.9)
My vaccine helps me to carry out my daily activitiesb 2.6 (1.3) 2 (1.1) 6.2 (6.1)
since being vaccinated i can go anywhere with my family or friendsb 2.5 (1.4) 2.1 (1.2) 6.2 (6)
getting vaccinated results in physical problems 2.7 (1.4) 2.1 (1) 6.2 (5)
Thanks to the treatment i understand my illness better 2.4 (1.3) 2.2 (1.1) 6.4 (6.2)
since being vaccinated the physical problems related with the  
allergy (sneezing, runny nose, headaches, itching) don’t bother me
3 (1.2) 2 (1) 6.5 (5)
Thanks to the vaccine, i am less dependent on always having  
to carry other medication (pills, inhalers, etc)b
2.9 (1.4) 2.1 (1.1) 6.8 (6)
Taking the vaccine daily does not involve any extra effort 3 (1.3) 2.3 (1.2) 6.8 (4.8)
Since taking the vaccine I do not find myself in compromising  
or uncomfortable situations caused by my allergy symptomsb
2.8 (1.2) 2.3 (1.1) 6.9 (5.5)
i am happy with the vaccine and having to travel and organize  
myself to get vaccinated does not present a problem
2.9 (1.2) 2.2 (1) 7 (4.9)
Thanks to the vaccine i no longer have to leave certain places  
because of my allergy symptoms
2.9 (1.2) 2.2 (1.1) 7.4 (5.9)
since being vaccinated i don’t have to avoid things that i like but  
which caused my allergyc
3 (1.2) 2.3 (1.1) 7.6 (6.2)
since being vaccinated i am no longer concerned about being  
in contact with the cause of my allergy
3.1 (1.2) 2.3 (2.8) 7.9 (11.9)
Notes: aimpact score = frequency × importance; bItem included in the final version; cThe item included in the prevalidated version of the new questionnaire is a linguistic 
reform of this item; the table includes 39 items after excluding the 11 items eliminated because of response distribution and the 20 worst score ranking items; the original 
tool has been developed entirely in Spanish; this is not an official version in English, but a translation for informational purposes only.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 3 Factor analysis for the 16 retained items of the new questionnaire (n = 254)a
Item loading 
1st factor
Item loading 
2nd factor
Item loading 
3rd factor
Item loading 
4th factor
since being vaccinated i can go anywhere with  
my family or friends
0.645 0.206 0.082 0.441
since being vaccinated i no longer have to avoid things 
that i like but which caused my allergy
0.858 0.071 0.213 0.074
My vaccine helps me to carry out my daily activities 0.561 0.493 0.135 0.292
Thanks to the vaccine i can work or study better 0.688 0.404 0.120 0.298
since being vaccinated i enjoy outdoor activities more 0.659 0.379 0.179 0.300
Since taking the vaccine I do not find myself in compromising  
or uncomfortable situations caused by my allergy symptoms
0.813 0.123 0.200 0.117
The good performance of the vaccine compensates for all the  
things i have to do to obtain it (appointments, prescriptions, leave)
0.178 0.835 0.224 0.207
The good performance of the vaccine compensates for 
the financial challenge it causes me
0.199 0.784 0.272 0.270
The good performance of the vaccine compensates for 
any inconveniences it could cause me
0.240 0.785 0.280 0.111
Generally speaking, I am satisfied with my allergy vaccine 0.305 0.463 0.635 0.322
in general, i would recommend the vaccine treatment 0.131 0.208 0.850 0.083
My quality of life has improved since receiving the vaccine 0.343 0.368 0.557 0.447
since being vaccinated against my allergy i have  
fewer symptoms
0.117 0.262 0.377 0.725
My vaccine works 0.257 0.414 0.543 0.533
Thanks to my vaccine, i am less dependent on always 
carrying other medication (pills, inhalers)
0.394 0.157 0.070 0.723
My vaccine works faster than i had expected 0.328 0.347 0.484 0.441
r2, % 55.60 9.46 5.45 4.27
Overall r2, % 74.79
Notes: aThe items belonging to each factor/dimension are highlighted in bold gray. Only the five items, highlighted in bold, substantially contributed (load $0.45) to a second 
factor. The final allocation of these five items to their respective dimensions was made by means of clinical criteria; the original tool was developed entirely in Spanish; this 
is not an official version in English, but a translation for informational purposes only.
Table 4 Score distributions, floor/ceiling effects, interscale correlations and internal consistency of the 16-retained items (n = 254)
GS PE AE CBB OS
items (n) 16 4 6 3 3
Mean 56.8 13.9 19.9 11.2 12.2
sD 14.7 3.8 6.3 3.3 2.8
Theoretical rangea 16–80 4–20 6–30 3–15 3–15
Observed range 16–79 4–20 6–30 3–15 3–15
Floorb (%) 0.4 2.4 4.3 2.4 0.4
ceilingc (%) 0 3.9 3.1 22.8 15.7
cA 0.94 0.79 0.89 0.89 0.83
interscale correlation range 0.822–0.904 
(cBB-Ae)
0.686–0.900 
(cBB-gs)
0.623–0.904 
(Os-gs)
0.632–0.822 
(Ae-gs)
0.623–0.86 
(Ae-gs)
inter-item correlation ranged 0.537–0.805 0.489–0.698 0.690–0.787 0.765–0.805 0.621–0.743
Notes: aOverall score ranges from 16 (low satisfaction) to 80 (high satisfaction). Low dimension score indicates low satisfaction while high dimension score indicates high 
satisfaction; bPercentage of patients with the worst possible score; cPercentage of patients with the best possible score; dcorrelation of corrected item-total.
Abbreviations: GS, Global score; PE, Perceived efficacy; AE, Activities and environment; CBB, Cost-benefit balance; OS, Overall satisfaction; CA, Cronbach’s alpha.
  triumvirate of “satisfaction”, “adherence”, and “abandon-
ment” of the treatment may go hand in hand. As some recent 
studies indicate,19,20 adherence to allergen-specific immuno-
therapy treatment would be below desired levels and would 
be conditioned by aspects related to, eg, inconvenience, 
ease of administration, cost, lack of efficacy, and adverse 
reactions, apart from the way the immunotherapy is admin-
istered, which suggests that the aspects mentioned feedback 
to and modulate the allergen-specific immunotherapy-treated 
allergic patient’s satisfaction, and, therefore, will affect the 
final result regarding the noncompliance or abandonment of 
the treatment prescribed by the allergologist.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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There are, at present, instruments to assess patient 
satisfaction with regard to chronic medication and general 
medication13–15 that identify relevant dimensions (ie, side 
effects, medication efficacy, or user convenience) with regard 
to patient satisfaction. Generally speaking, these dimen-
sions could be considered as standard for and common to 
any patient receiving medication for any illness. However, 
these scales could be limited when capturing all the patient 
perceptions associated with the special characteristics of 
treatment employed with certain illnesses, as would be the 
case in allergic patients undergoing specific immunotherapy 
  treatment. That is probably why quite a few questionnaires 
have been developed to measure treatment satisfaction 
specific for certain illnesses and patient populations.4–12 
Yet, how can we assess the specific immunotherapy-treated 
allergic patient satisfaction, and his/her relation to other basic 
parameters in the clinical management of this population, 
without having a suitable instrument available? That is why 
the research team proposed developing what will probably 
turn out to be the first satisfaction instrument with regard to 
the specific immunotherapy of allergic adult patients.
The new questionnaire has been originally developed 
using Spanish-speaking adult patients from Spain (its 
eventual application to Spanish speakers within a Hispanic 
culture would be relatively easy after correction for cultural 
adaptation according to the agreed-upon guidelines for this 
purpose).34 Right from the very beginning, the research team 
proposed to strictly follow the present standards recom-
mended for any instruments set out in PRO.35 In this way, 
the patient perspective has been included in all the phases 
described in this article relative to item generation and 
reduction (with the sole exception of the six items eliminated 
on the basis of clinical qualitative criteria, mainly because 
the statistical and quantitative arguments did not allow the 
Table 5 Mean (sD) of the 16-retained itemsa, based on symptomatic manifestations of allergy (n = 254)
Global 
score
Perceived 
efficacy
Activities and 
environment
Cost-benefit 
balance
General 
satisfaction
Type of allergic rhinitis
intermittent 58.3 (14.3) 14.3 (3.7) 20.4 (6.3) 11.7 (3.3) 12.5 (2.7)
Persistent 53.5 (15.2) 13.1 (3.9) 18.9 (6.3) 10.5 (3.3) 11.5 (2.9)
P-valueb 0.042 0.009 0.055 0.002 0.027
Intensity of allergic rhinitis (ARIA)
Mild 60.1 (13.2) 14.9 (3.4) 19.9 (6.8) 11.8 (3.3) 12.8 (2.6)
Moderate/severe 55.2 (15.2) 13.5 (3.9) 20 (6.1) 11 (3.3) 11.9 (2.8)
P-valueb 0.049 0.008 0.922 0.039 0.031
Presence of bothersome symptoms (ARIA)
no 59.6 (13.3) 14.7 (3.5) 20.4 (6.7) 11.7 (3.2) 12.6 (2.6)
Yes 54.8 (15.3) 13.4 (3.9) 19.7 (6) 10.9 (3.3) 11.8 (2.8)
P-valueb 0.039 0.010 0.223 0.033 0.058
Rhinorrhea
no 61.6 (12.2) 15.3 (3.2) 21.5 (6.9) 12.8 (3) 13.1 (2.1)
Yes 55.8 (15) 13.6 (3.8) 19.6 (6.2) 10.9 (3.2) 12 (2.8)
P-valueb 0.064 0.011 0.036 0.000 0.073
Intensity of rhinorrhea
Absence of symptoms 61.6 (12.2) 15.3 (3.2) 21.5 (6.9) 12.8 (3) 13.1 (2.1)
Mild symptoms 57.7 (14.2) 13.9 (4.1) 19.8 (6.3) 11.5 (3.3) 12.5 (2.7)
Moderate symptoms 54.3 (14.7) 13.4 (3.4) 19.3 (6) 10.5 (3.1) 11.4 (2.9)
severe symptoms 53.9 (16.9) 13.4 (4) 19.7 (6.2) 10.5 (3.2) 11.7 (3)
P-valuec 0.150 0.038 0.180 0.000 0.044
Sneezing 
no 63.2 (11.9) 16.2 (2.7) 21 (7.3) 12.8 (3) 13.7 (1.6)
Yes 55.9 (14.8) 13.5 (3.8) 19.7 (6.1) 11 (3.3) 12 (2.8)
P-valueb 0.051 0.000 0.177 0.002 0.010
Intensity of sneezing
Absence of symptoms 63.2 (11.9) 16.2 (2.7) 21 (7.3) 12.8 (3) 13.7 (1.6)
Mild symptoms 56.4 (14) 13.6 (3.7) 19.7 (6.4) 11.5 (3.3) 12.1 (2.6)
Moderate symptoms 56.2 (13.9) 13.5 (3.5) 20.3 (5.6) 10.7 (3.1) 11.8 (2.8)
severe symptoms 55 (17.3) 13.5 (4.3) 19.1 (6.5) 10.8 (3.3) 12.1 (3.2)
P-valuec 0.281 0.006 0.410 0.004 0.050
Notes: aOverall score ranges from 16 (low satisfaction) to 80 (high satisfaction). Low dimension score indicates low satisfaction while high dimension score indicates high 
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establishment of relevant differences between them). We 
believe that the patient perspective has contributed to the 
validity of the questionnaire’s content, as well as concentrat-
ing the content of the measure on those aspects relevant to 
the patient at the time of assessing his/her satisfaction with 
allergen-specific immunotherapy.
Also, a strength of our study includes the use of a range 
of sources to generate items for inclusion in the initial item 
pool, and the explicit incorporation of the views of the poten-
tial users of the questionnaire (allergologists) right from the 
start of the development process. The use of a clinimetric 
analysis also ensured that the most frequently occurring 
and/or most relevant items were included in the question-
naire, although there is no consensus with respect to which 
of the item reduction method processes is the most suitable.36 
The final version of the instrument contains 16 items, which 
clinicians participating in the development process felt was 
a suitable number for use in clinical practice. This measure 
has been developed with the belief of converting it into a 
real instrument for the physicians who normally manage 
allergic patients with allergen-specific immunotherapy. For 
this reason, two other aspects considered relevant by clini-
cians, and that were borne in mind during the development 
of the measure, were that the questionnaire should be easy 
to use and score.
The results of the preliminary analysis on the psychometric 
properties of the new measure provide satisfactory evidence 
with respect to the feasibility, reliability, and validity of the 
questionnaire, although their testing was not the main goal 
of these phases of the project, neither was the study design 
adapted to this. On the one hand, only a low percentage of 
patients (,5%) obtained the worst or the best possible over-
all and dimension scores, which suggests that the question-
naire satisfactorily covers the satisfaction level of the target 
population under study. It can also be taken as an indication 
of whether a measure will, at least theoretically, be capable 
of reflecting changes for better or worse, within acceptable 
limits in all dimensions, with fewer than 15% of patients hav-
ing either the maximum or the minimum score in any of the 
dimensions or the overall score.37 This is true except for the 
cost-benefit balance dimension in which 23% of the sample 
patients got the highest (best) possible score. This is an aspect 
which should be re-assessed in the validation study that is being 
developed, and which would confirm effectively whether the 
content and cover of this dimension is insufficient to capture 
the existing satisfaction of a part of the study target.
On the other hand, the Cronbach’s alpha coefficients 
obtained were satisfactory. The Cronbach’s alpha values 
for all the dimensions and for the overall score exceeded the 
suggested minimum of 0.70 for use at group level.26,27 The 
overall score exceeded 0.90, which has been suggested as 
being the threshold for a questionnaire of this type when used 
at the individual level.37 This is particularly important, given 
that the aim of the study was to produce a questionnaire that 
could be used to assess and monitor individual patients in 
clinical practice. However, bearing in mind that the values 
being reported were obtained within the context of the item 
reduction study, ie, from patients who answered 70 items 
twice, these values could change when patients complete the 
final version of the questionnaire and are required to respond, 
only once, to each of the 16 items.
The principal component analysis done on the 16 retained 
items yielded a good factorial solution, identifying four fac-
tors, the items for which were reasonably well grouped with 
regard to their content and the conceptual frame correspond-
ing to the assessment of patient satisfaction with treatment. 
This result supports the evidence that the new questionnaire 
has good structural validity and reflects the multidimen-
sionality of the concept, very much in agreement with those 
proposed in the most significant revisions.9,38–41 In this sense, 
the new instrument includes items about treatment-related 
effectiveness and symptom relief, functioning, discomfort, 
and side effects, cost and accessibility to treatment, and 
general satisfaction. All the aforementioned are topics 
or domains habitually related to patient satisfaction with 
treatment,25–29 together with other aspects initially included 
in the initial item pool, and which were eliminated at some 
time during the item reduction process (eg, disease-related 
information or regimen characteristics).
Moreover, the preliminary validity analysis of known 
groups showed that the new tool’s scores behave coher-
ently within the expectable, with regard to the compared 
and defined groups.
A limitation of our study could be the eventual limited 
number of focus groups used for the item-generation phase. 
However, the concept to be measured (satisfaction with 
  allergen-specific immunotherapy among allergic adult 
patients) seems to be a reasonably limited concept, and 
presumably it has been sufficiently well represented for the 
purpose of the study because the saturation of issues raised 
in different focus groups was high. On the other hand, the 
sample size available for exploring the preliminary validity of 
the questionnaire probably does not have sufficient statistical 
power to be able to identify as statistically significant some 
differences found in this analysis, because the main aim of 
the field work was to reduce items. Lastly, an exhaustive Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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assessment of psychometric properties should be performed 
in the future before reliably reaching conclusions about the 
usefulness of the new measure. A formal validation process 
is currently in progress.
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